Navigation Links
Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
Date:10/30/2008

CAMBRIDGE, Mass., Oct. 30 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today reported unaudited financial results for the third quarter and nine months ended September 30, 2008. At September 30, 2008, Idenix's cash, cash equivalents and marketable securities totaled approximately $60.1 million.

2008 Year-to-Date Business Highlights

-- Idenix completed its phase I/II study of IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed for the treatment of HIV-1, which demonstrated potent antiviral activity at all doses tested. Patients receiving once-daily IDX899 achieved a mean plasma viral load reduction of approximately 1.8 log10 after seven days of treatment in each of the 800 mg, 400 mg, 200 mg and 100 mg dosing cohorts (n=8 per treatment group). Patients receiving placebo (n=8) had a mean viral load increase of 0.10 log10 over the same treatment period. The safety profile of IDX899 observed during this study was comparable to placebo, with no serious adverse events reported and no pattern of adverse events or laboratory abnormalities observed on treatment. Additionally, no patients who received treatment discontinued the study.

-- Idenix also continued to advance its HCV discovery and development programs, successfully completing a first-in-man phase I study of IDX184, a nucleotide prodrug candidate, and initiating the IND-enabling preclinical studies for IDX375, a non-nucleoside polymerase inhibitor, and IDX136 and IDX316, macrocyclic protease inhibitor drug candidates.

"As we advance our HCV and HIV discovery and devel
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
2. Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results
3. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
4. Idenix to Host Conference Call Discussing Fourth Quarter 2007 Financial Results
5. Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)
6. Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Idenix Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference
9. Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
10. Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
11. Idenix to Host Conference Call Discussing Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Massachusetts (PRWEB) October 22, 2014 ... announced the release of a new infographic, Understanding ... to create a beautifully designed, easy to follow informative ... transmission, areas of outbreak, symptoms and prevention. , "As ... discovered that the 2014 Ebola outbreak represents not only ...
(Date:10/22/2014)... According to new market research report "Cloud Professional ... & Support), by Service Model (SaaS, PaaS, IaaS), ... & Community)) - Global Forecast to 2019", published ... Services Market into various sub-segments with an in-depth ... the drivers and restraints for this market with ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 ... enterprise, announced today that rare disease expert John ... president, research. Dr. McKew brings more than two decades ... at the National Institutes of Health, Wyeth Research and ... McKew will lead aTyr,s efforts to expand and translate ...
(Date:10/20/2014)... ON , Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: ... $1.7 million which brings Q3 orders to $5.8 million and provides ... control projects in North America and one ... continue to bid new projects at record levels," said Peter ... were higher at the end of Q3 than they have been ...
Breaking Biology Technology:Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
... Corp. Ltd., a developer and marketer of innovative products ... today announced that Gary Levine has been appointed Chief ... has joined the company as Director of Reagents Development ... Martin, ZyGEM is developing an innovative Rapid DNA analysis ...
... have created a working cloaking device that not only ... but also boasts unique features; it has an ,on ... The researchers, from the University of Dallas, Texas, ... in a fascinating video shown here http://www.youtube.com/watch?v=3YO4TTpYg7g ...
... Agendia, an innovative molecular cancer diagnostics company, ... routine inspection of its Irvine, California-based laboratories by the ... 510(k) clearance for its MammaPrint® breast cancer recurrence test ... test of its kind to receive FDA clearance, which, ...
Cached Biology Technology:ZyGEM Strengthens Senior Management Team With New Appointments 2ZyGEM Strengthens Senior Management Team With New Appointments 3'Mirage-effect' helps researchers hide objects 2Agendia Successfully Completes Bi-Annual FDA Inspection 2
(Date:10/15/2014)... admitted Johannes Gutenberg University Mainz (JGU) as a ... continues to maintain a significant nationwide standing in ... acceptance of Johannes Gutenberg University Mainz as a ... in the national and international competition for the ... Rhineland-Palatinate can be proud that Mainz University has ...
(Date:10/15/2014)... Conn. , Oct. 15, 2014 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce market releases ... MarketSite in Times Square on Monday October 13 th . ... CTO David Tunnel and angel investor Mr. Chad ... Pereira , CEO of NXT-ID thanked his investors and employees "for ...
(Date:10/14/2014)... – Like discriminating thieves, prostate cancer tumors scavenge and ... body. But such avarice may be a fatal weakness. ... way to kill prostate cancer cells by delivering a ... destroys the diseased cells brimming with the mineral, leaving ... two drugs already commercially available for other uses, could ...
Breaking Biology News(10 mins):Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3Prostate cancer's penchant for copper may be a fatal flaw 2
... platform, complete with biometric enrollment, authentication, data ... formatting, and background check connectivity, BEDFORD, ... (Nasdaq: AWRE ), a global provider of biometrics ... with Sun identity management solutions. The integration of,BioSP with ...
... Natural selection . . . By examining ... Oak Ridge National Laboratory hope to develop a strategy ... a process known as association mapping, scientists will attempt ... growing in natural populations with the goal being to ...
... research team in Antarctica led by David Marchant, ... University, has reported the discovery of exceptionally well-preserved ... as diatoms, small fresh water crustaceans, and insects ... the southernmost region of the continent before a ...
Cached Biology News:Sun Microsystems and Aware, Inc. Announce Integration of Aware's BioSP with Sun Identity Management Solutions 2Sun Microsystems and Aware, Inc. Announce Integration of Aware's BioSP with Sun Identity Management Solutions 3Sun Microsystems and Aware, Inc. Announce Integration of Aware's BioSP with Sun Identity Management Solutions 4Sun Microsystems and Aware, Inc. Announce Integration of Aware's BioSP with Sun Identity Management Solutions 5Story tips from the US Department of Energy's Oak Ridge National Laboratory, August 2008 2Story tips from the US Department of Energy's Oak Ridge National Laboratory, August 2008 3Rare Antarctic fossils reveal extinction of tundra before full polar climate arrived 2Rare Antarctic fossils reveal extinction of tundra before full polar climate arrived 3
Recombinant Viral CCI/Fc Chimera, CF...
... Pig serum is collected from fasted Guinea Pigs. ... Citrate N-04: Heparin (Na) N-06: ... N-10: EDTA (Na) N-03: Alsevers ... N-09: K3EDTA N-11: Heparin ...
GENOMIPHI V2 DNA AMP KIT 25RXN, 1 EA. Category: Genomics DNA Amplification....
EPH electrode, anode, 1. Category: Electrophoresis Systems & Standards & Reagents, IEF & SDS-PAGE & 2-D Electrophoresis, Multiphor II Kits & Components and Accessories....
Biology Products: